Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after sublingual administration of midazolam

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 19, 2011, Pages 1668-1676

  Kaartama, Ruut ^a   Jarho, Pekka ^a   Savolainen, Jouko ^b   Kokki, Hannu ^a,c   Lehtonen, Marko ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Oy Fennopharma Ltd   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

1 Hydroxymidazolam; GC MS; Midazolam; Mixed mode SPE; Negative chemical ionization; Sublingual administration

Indexed keywords

1-HYDROXYMIDAZOLAM; GC-MS; MIDAZOLAM; MIXED-MODE SPE; NEGATIVE CHEMICAL IONIZATION; SUBLINGUAL ADMINISTRATION;

CHEMICAL ANALYSIS; COLUMN CHROMATOGRAPHY; DEGRADATION; EXTRACTION; GAS CHROMATOGRAPHY; IONIZATION OF GASES; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLISM; METABOLITES; METHANE; PEDIATRICS;

ANESTHETICS;

ALPHA HYDROXYMIDAZOLAM; DRUG METABOLITE; METHANE; MIDAZOLAM;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; RABBIT; ROOM TEMPERATURE; SOLID PHASE EXTRACTION;

ADMINISTRATION, SUBLINGUAL; ANIMALS; AREA UNDER CURVE; DRUG STABILITY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METHANE; MIDAZOLAM; RABBITS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

ORYCTOLAGUS CUNICULUS;

EID: 79955883971     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.04.009     Document Type: Article

References (40)

1. Payne K., Mattheyse F.J., Liebenberg D., Dawes T. Eur. J. Clin. Pharmacol. 1989, 37:267.
2. Schwagmeier R., Alincic S., Striebel H.W. Br. J. Clin. Pharmacol. 1998, 46:203.
3. Rey E., Delaunay L., Pons G., Murat I., Richard M.O., Saint-Maurice C., Olive G. Eur. J. Clin. Pharmacol. 1991, 41:355.
4. Burstein A.H., Modica R., Hatton M., Forrest A., Gengo F.M. J. Clin. Pharmacol. 1997, 37:711.
5. Geldner G., Hubmann M., Knoll R., Jacobi K. Paediatr. Anaesth. 1997, 7:103.
6. Karl H.W., Rosenberger J.L., Larach M.G., Ruffle J.M. Anesthesiology 1993, 78:885.
7. Kutlu N.O., Dogrul M., Yakinci C., Soylu H. Brain Dev. 2003, 25:275.
8. McIntyre J., Robertson S., Norris E., Appleton R., Whitehouse W.P., Phillips B., Martland T., Berry K., Collier J., Smith S., Choonara I. Lancet 2005, 366:205.
9. Feld L.H., Negus J.B., White P.F. Anesthesiology 1990, 73:831.
10. The European Agency for the Evaluation of Medicinal Products, Assessment of the paediatric needs anaesthesiology, Doc. Ref: EMEA/405166/2006, 2006, available at, http://www.emea.europa.eu.
11. Antiepileptic Drugs 2002, Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106, USA. 5th ed. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
12. Gerecke M. Br. J. Clin. Pharmacol. 1983, 16(Suppl. (1)):11S.
13. Frison G., Tedeschi L., Maietti S., Ferrara S.D. Rapid Commun. Mass Spectrom. 2001, 15:2497.
14. Drummer O. J. Chromatogr. B 1998, 713:201.
15. Lai C.-K., Lee T., Au K.-M., Chan A.Y.-W. Clin. Chem. 1997, 43:312.
16. Eeckhoudt S.L., Desager J.P., Horsmans Y., De Winne A.J., Verbeeck R.K. J. Chromatogr. B 1998, 710:165.
17. Elbarbry F., Attia A., Shoker A. J.Pharm. Biomed. Anal. 2009, 50:987.
18. Lehmann B., Boulieu R. J. Chromatogr. B 1995, 674:138.
19. Raikos N., Theodoridis G., Alexiadou E., Gika H., Argiriadou H., Parlapani H., Tsoukali H. J. Sep. Sci. 2009, 32:1018.
20. Gaillard Y., Gay-Montchamp J.P., Ollagnier M. J. Chromatogr. 1993, 622:197.
21. Gunnar T., Ariniemi K., Lillsunde P. J. Mass Spectrom. 2005, 40:739.
22. Eap C.B., Bouchoux G., Powell Golay K., Baumann P. J. Chromatogr. B 2004, 802:339.
23. Gunnar T., Ariniemi K., Lillsunde P. J. Mass Spectrom. 2006, 41:741.
24. Miyaguchi H., Kuwayama K., Tsujikawa K., Kanamori T., Iwata Y.T., Inoue H., Kishi T. Forensic Sci. Int. 2006, 157:57.
25. Ishida T., Kudo K., Hayashida M., Ikeda N. J. Chromatogr. B 2009, 877:2652.
26. Sano T., Sato K., Kurihara R., Mizuno Y., Kojima T., Yamakawa Y., Yamada T., Ishii A., Katsumata Y. Leg. Med. 2001, 3:149.
27. Frerichs V.A., Zaranek C., Haas C.E. J. Chromatogr. B 2005, 824:71.
28. Quintela O., Sauvage F.-L., Charvier F., Gaulier J.-M., Lachâtre G., Marquet P. Clin. Chem. 2006, 52:1346.
29. Zhang S., Song N., Li Q., Fan H., Liu C. J. Chromatogr. B 2008, 871:78.
30. Dostalek M., Macwan J.S., Chitnis S.D., Ionita I.A., Akhlaghi F. J. Chromatogr. B 2010, 878:1629.
31. Schafroth M., Thormann W., Allemann D. Electrophoresis 1994, 15:72.
32. Lausecker B., Hopfgartner G., Hesse M. J. Chromatogr. B 1998, 718:1.
33. Zhao Y., Lam M., Wu D., Mak R. Rapid Commun. Mass Spectrom. 2008, 22:3217.
34. Kapron J.T., Pace E., Van Pelt C.K., Henion J. Rapid Commun. Mass Spectrom. 2003, 17:2019.
35. Schuhmacher J., Zimmer D., Tesche F., Pickard V. Rapid Commun. Mass Spectrom. 2003, 17:1950.
36. Matuszewski B.K. J. Chromatogr. B 2006, 830:293.
37. Kumar A., Mann H.J., Remmel R.P. J. Chromatogr. B 2007, 853:287.
38. Guidance for Industry, Bioanalytical Methods Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001, available at http://www.fda.gov/.
39. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98, 2000, available at, http://www.ema.europa.eu.
40. Maurer H.H. Ther. Drug Monit. 2002, 24:247.